Skip to main content
Top
Published in: Endocrine 2/2021

01-02-2021 | Glucocorticoid | Original Article

The effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments

Authors: Victor Brun Boesen, Stina Willemoes Borresen, Thea Christoffersen, Marianne Klose, Torquil Watt, Ulla Feldt-Rasmussen

Published in: Endocrine | Issue 2/2021

Login to get access

Abstract

Purpose

Replicating the physiological cortisol secretion is key in the treatment of glucocorticoid insufficient individuals and optimization may enhance quality of life. The study investigates fatigue measured by ecological momentary assessments in patients treated with conventional hydrocortisone compared with once-daily dual-release hydrocortisone (Plenadren).

Methods

A 21-week open-label switch pilot trial included 30 patients with adrenal insufficiency due to hypopituitarism. Fatigue was assessed four times daily for 20 days using a momentary item version of the Multidimensional Fatigue Inventory on patients’ usual hydrocortisone regimen. Participants switched treatment to an identical daily dose of Plenadren for 16 weeks where fatigue assessments were repeated. Change in fatigue and diurnal variation of fatigue was analyzed using mixed models for repeated measurements.

Results

In four out of five fatigue subscales fatigue was significantly reduced 0.7–1.1 points (scales ranging from 4 to 20), when treated with Plenadren compared with conventional hydrocortisone, corresponding to small effect sizes below the scale-specific minimal important changes. However, 33% of the participants completing the study (9/27) experienced reductions in fatigue above the minimal important change. On Plenadren, we found larger between-person variances and smaller within-person variances. Finally, we identified diurnal fatigue curves for both treatments.

Conclusions

The Plenadren-related reduction in fatigue was significant but not necessarily of clinical importance when looking at a group level. However, there was a large interindividual variation in treatment effect, why patients with a large benefit in quality of life should be identified. Future RCTs should be powered to detect the effect magnitudes identified here.
Literature
1.
go back to reference H. Filipsson, J.P. Monson, M. Koltowska-Häggström, A. Mattsson, G. Johannsson, The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J. Clin. Endocrinol. Metab. 91, 3954 (2006).CrossRef H. Filipsson, J.P. Monson, M. Koltowska-Häggström, A. Mattsson, G. Johannsson, The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J. Clin. Endocrinol. Metab. 91, 3954 (2006).CrossRef
2.
go back to reference R. Giordano, S. Marzotti, M. Balbo, S. Romagnoli, E. Marinazzo, R. Berardelli, G. Migliaretti, A. Benso, A. Falorni, E. Ghigo, E. Arvat, Metabolic and cardiovascular profile in patients with Addison’s disease under conventional glucocorticoid replacement. J. Endocrinol. Investig. 32, 917 (2009).CrossRef R. Giordano, S. Marzotti, M. Balbo, S. Romagnoli, E. Marinazzo, R. Berardelli, G. Migliaretti, A. Benso, A. Falorni, E. Ghigo, E. Arvat, Metabolic and cardiovascular profile in patients with Addison’s disease under conventional glucocorticoid replacement. J. Endocrinol. Investig. 32, 917 (2009).CrossRef
3.
go back to reference L. Leelarathna, L. Breen, J.K. Powrie, S.M. Thomas, R. Guzder, B. McGowan, P.V. Carroll, Co-morbidities, management and clinical outcome of auto-immune Addison’s disease. Endocrine 38, 113 (2010).CrossRef L. Leelarathna, L. Breen, J.K. Powrie, S.M. Thomas, R. Guzder, B. McGowan, P.V. Carroll, Co-morbidities, management and clinical outcome of auto-immune Addison’s disease. Endocrine 38, 113 (2010).CrossRef
4.
go back to reference J.W. Buning, M.Van. Faassen, P. Brummelman, R.P.F. Dullaart, G. Van Den Berg, M.M. Van Der Klauw, M.N. Kerstens, C.A. Stegeman, A.C.M. Kobold, I.P. Kema, B.H.R. Wolffenbuttel, A.P.Van. Beek, Effects of hydrocortisone on the regulation of blood pressure: results from a randomized controlled trial. J. Clin. Endocrinol. Metab. 101, 3691 (2016).CrossRef J.W. Buning, M.Van. Faassen, P. Brummelman, R.P.F. Dullaart, G. Van Den Berg, M.M. Van Der Klauw, M.N. Kerstens, C.A. Stegeman, A.C.M. Kobold, I.P. Kema, B.H.R. Wolffenbuttel, A.P.Van. Beek, Effects of hydrocortisone on the regulation of blood pressure: results from a randomized controlled trial. J. Clin. Endocrinol. Metab. 101, 3691 (2016).CrossRef
5.
go back to reference E. Charmandari, N.C. Nicolaides, G.P. Chrousos, Adrenal insufficiency. Lancet 383, 2152 (2014).CrossRef E. Charmandari, N.C. Nicolaides, G.P. Chrousos, Adrenal insufficiency. Lancet 383, 2152 (2014).CrossRef
6.
go back to reference A. Mallappa, M. Debono, Endocrine development: workshop, Rome, October 2014. Endocr. Dev. 30, 42 (2016).CrossRef A. Mallappa, M. Debono, Endocrine development: workshop, Rome, October 2014. Endocr. Dev. 30, 42 (2016).CrossRef
7.
go back to reference S.R. Bornstein, B. Allolio, W. Arlt, A. Barthel, A. Don-Wauchope, G.D. Hammer, E.S. Husebye, D.P. Merke, M.H. Murad, C.A. Stratakis, D.J. Torpy, Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 364 (2016).CrossRef S.R. Bornstein, B. Allolio, W. Arlt, A. Barthel, A. Don-Wauchope, G.D. Hammer, E.S. Husebye, D.P. Merke, M.H. Murad, C.A. Stratakis, D.J. Torpy, Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 364 (2016).CrossRef
8.
go back to reference K. Løvås, J.H. Loge, E.S. Husebye, Subjective health status in Norwegian patients with Addison’s disease*: Subjective health status in Addison’s disease. Clin. Endocrinol. (Oxf.) 56, 581 (2002).CrossRef K. Løvås, J.H. Loge, E.S. Husebye, Subjective health status in Norwegian patients with Addison’s disease*: Subjective health status in Addison’s disease. Clin. Endocrinol. (Oxf.) 56, 581 (2002).CrossRef
9.
go back to reference S. Hahner, M. Loeffler, M. Fassnacht, D. Weismann, A.C. Koschker, M. Quinkler, O. Decker, W. Arlt, B. Allolio, Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J. Clin. Endocrinol. Metab. 92, 3912 (2007).CrossRef S. Hahner, M. Loeffler, M. Fassnacht, D. Weismann, A.C. Koschker, M. Quinkler, O. Decker, W. Arlt, B. Allolio, Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J. Clin. Endocrinol. Metab. 92, 3912 (2007).CrossRef
10.
go back to reference B. Bleicken, S. Hahner, M. Loeffler, M. Ventz, B. Allolio, M. Quinkler, Impaired subjective health status in chronic adrenal insufficiency: Impact of different glucocorticoid replacement regimens. Eur. J. Endocrinol. 159, 811 (2008).CrossRef B. Bleicken, S. Hahner, M. Loeffler, M. Ventz, B. Allolio, M. Quinkler, Impaired subjective health status in chronic adrenal insufficiency: Impact of different glucocorticoid replacement regimens. Eur. J. Endocrinol. 159, 811 (2008).CrossRef
11.
go back to reference B. Bleicken, S. Hahner, M. Loeffler, M. Ventz, O. Decker, B. Allolio, M. Quinkler, Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clin. Endocrinol. (Oxf.) 72, 297 (2010).CrossRef B. Bleicken, S. Hahner, M. Loeffler, M. Ventz, O. Decker, B. Allolio, M. Quinkler, Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clin. Endocrinol. (Oxf.) 72, 297 (2010).CrossRef
12.
go back to reference M. Forss, G. Batcheller, S. Skrtic, G. Johannsson, Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency-a worldwide patient survey. BMC Endocr. Disord. 12, 8 (2012).CrossRef M. Forss, G. Batcheller, S. Skrtic, G. Johannsson, Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency-a worldwide patient survey. BMC Endocr. Disord. 12, 8 (2012).CrossRef
13.
go back to reference G. Johannsson, A.G. Nilsson, R. Bergthorsdottir, P. Burman, P. Dahlqvist, B. Ekman, B.E. Engström, T. Olsson, O. Ragnarsson, M. Ryberg, J. Wahlberg, B.M.K. Biller, J.P. Monson, P.M. Stewart, H. Lennernäs, S. Skrtic, Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J. Clin. Endocrinol. Metab. 97, 473 (2012).CrossRef G. Johannsson, A.G. Nilsson, R. Bergthorsdottir, P. Burman, P. Dahlqvist, B. Ekman, B.E. Engström, T. Olsson, O. Ragnarsson, M. Ryberg, J. Wahlberg, B.M.K. Biller, J.P. Monson, P.M. Stewart, H. Lennernäs, S. Skrtic, Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J. Clin. Endocrinol. Metab. 97, 473 (2012).CrossRef
14.
go back to reference V. Guarnotta, A. Ciresi, G. Pillitteri, C. Giordano, Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month retrospective analysis. Clin. Endocrinol. (Oxf.). 88, 665 (2018).CrossRef V. Guarnotta, A. Ciresi, G. Pillitteri, C. Giordano, Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month retrospective analysis. Clin. Endocrinol. (Oxf.). 88, 665 (2018).CrossRef
15.
go back to reference V. Guarnotta, C. Di Stefano, A. Santoro, A. Ciresi, A. Coppola, C. Giordano, Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency. Endocr. Connect. 8, 853 (2019).CrossRef V. Guarnotta, C. Di Stefano, A. Santoro, A. Ciresi, A. Coppola, C. Giordano, Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency. Endocr. Connect. 8, 853 (2019).CrossRef
16.
go back to reference R. Giordano, F. Guaraldi, E. Marinazzo, F. Fumarola, A. Rampino, R. Berardelli, I. Karamouzis, M. Lucchiari, T. Manetta, G. Mengozzi, E. Arvat, E. Ghigo, Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison’s disease. Endocrine 51, 360 (2016).CrossRef R. Giordano, F. Guaraldi, E. Marinazzo, F. Fumarola, A. Rampino, R. Berardelli, I. Karamouzis, M. Lucchiari, T. Manetta, G. Mengozzi, E. Arvat, E. Ghigo, Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison’s disease. Endocrine 51, 360 (2016).CrossRef
17.
go back to reference A.M. Isidori, M.A. Venneri, C. Graziadio, C. Simeoli, D. Fiore, V. Hasenmajer, E. Sbardella, D. Gianfrilli, C. Pozza, P. Pasqualetti, S. Morrone, A. Santoni, F. Naro, A. Colao, R. Pivonello, A. Lenzi, Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 6, 173 (2018).CrossRef A.M. Isidori, M.A. Venneri, C. Graziadio, C. Simeoli, D. Fiore, V. Hasenmajer, E. Sbardella, D. Gianfrilli, C. Pozza, P. Pasqualetti, S. Morrone, A. Santoni, F. Naro, A. Colao, R. Pivonello, A. Lenzi, Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 6, 173 (2018).CrossRef
18.
go back to reference M. Quinkler, R.M. Nilsen, K. Zopf, M. Ventz, M. Øksnes, Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur. J. Endocrinol. 172, 619 (2015).CrossRef M. Quinkler, R.M. Nilsen, K. Zopf, M. Ventz, M. Øksnes, Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur. J. Endocrinol. 172, 619 (2015).CrossRef
19.
go back to reference A.G. Nilsson, R. Bergthorsdottir, P. Burman, P. Dahlqvist, B. Ekman, B.E. Engström, O. Ragnarsson, S. Skrtic, J. Wahlberg, H. Achenbach, S. Uddin, C. Marelli, G. Johannsson, Long-Term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: A phase 3b, open-label, extension study. Eur. J. Endocrinol. 176, 715 (2017).CrossRef A.G. Nilsson, R. Bergthorsdottir, P. Burman, P. Dahlqvist, B. Ekman, B.E. Engström, O. Ragnarsson, S. Skrtic, J. Wahlberg, H. Achenbach, S. Uddin, C. Marelli, G. Johannsson, Long-Term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: A phase 3b, open-label, extension study. Eur. J. Endocrinol. 176, 715 (2017).CrossRef
20.
go back to reference F. Ceccato, E. Selmin, C. Sabbadin, M. Dalla Costa, G. Antonelli, M. Plebani, M. Barbot, C. Betterle, M. Boscaro, C. Scaroni, Improved salivary cortisol rhythm with dual-release hydrocortisone. Endocr. Connect. 7, 965 (2018).CrossRef F. Ceccato, E. Selmin, C. Sabbadin, M. Dalla Costa, G. Antonelli, M. Plebani, M. Barbot, C. Betterle, M. Boscaro, C. Scaroni, Improved salivary cortisol rhythm with dual-release hydrocortisone. Endocr. Connect. 7, 965 (2018).CrossRef
21.
go back to reference M. Øksnes, S. Bensing, A.L. Hulting, O. Kam̈pe, A. Hackemann, G. Meyer, K. Badenhoop, C. Betterle, A. Parolo, R. Giordano, A. Falorni, L. Papierska, W. Jeske, A.A. Kasperlik-Zaluska, V.K.K. Chatterjee, E.S. Husebye, K. Løvas, Quality of life in European patients with Addison’s disease:Validity of the disease-specific questionnaire AddiQoL. J. Clin. Endocrinol. Metab. 97, 568 (2012).CrossRef M. Øksnes, S. Bensing, A.L. Hulting, O. Kam̈pe, A. Hackemann, G. Meyer, K. Badenhoop, C. Betterle, A. Parolo, R. Giordano, A. Falorni, L. Papierska, W. Jeske, A.A. Kasperlik-Zaluska, V.K.K. Chatterjee, E.S. Husebye, K. Løvas, Quality of life in European patients with Addison’s disease:Validity of the disease-specific questionnaire AddiQoL. J. Clin. Endocrinol. Metab. 97, 568 (2012).CrossRef
22.
go back to reference A. Stone, S. Shiffman, A. Atienza, L. Nebeling, The science of real-time data capture: self-reports in health research (Oxford University Press, Oxford; 2007). A. Stone, S. Shiffman, A. Atienza, L. Nebeling, The science of real-time data capture: self-reports in health research (Oxford University Press, Oxford; 2007).
23.
go back to reference V.B. Boesen, U. Feldt-Rasmussen, J. Bue Bjorner, P. Cramon, M. Groenvold, B. Nygaard, Å.K. Rasmussen, T. Vilsbøll, T. Watt, How should thyroid-related quality of life be assessed? Recalled patient-reported outcomes compared to here-and-now measures. Thyroid 28, 1561 (2018).CrossRef V.B. Boesen, U. Feldt-Rasmussen, J. Bue Bjorner, P. Cramon, M. Groenvold, B. Nygaard, Å.K. Rasmussen, T. Vilsbøll, T. Watt, How should thyroid-related quality of life be assessed? Recalled patient-reported outcomes compared to here-and-now measures. Thyroid 28, 1561 (2018).CrossRef
24.
go back to reference P. Lorenz, L. Schindler, S. Steudte-Schmiedgen, K. Weidner, C. Kirschbaum, J. Schellong, Ecological momentary assessment in posttraumatic stress disorder and coping. An eHealth study protocol. Eur. J. Psychotraumatol. 10, 1654064 (2019)CrossRef P. Lorenz, L. Schindler, S. Steudte-Schmiedgen, K. Weidner, C. Kirschbaum, J. Schellong, Ecological momentary assessment in posttraumatic stress disorder and coping. An eHealth study protocol. Eur. J. Psychotraumatol. 10, 1654064 (2019)CrossRef
25.
go back to reference P. Solk, K. Gavin, J. Fanning, W. Welch, G. Lloyd, A. Cottrell, A. Nielsen, C.A.Santa. Maria, W. Gradishar, S.A. Khan, S. Kulkarni, J. Siddique, S.M. Phillips, Feasibility and acceptability of intensive longitudinal data collection of activity and patient-reported outcomes during chemotherapy for breast cancer. Qual. Life Res 28, 3333 (2019).CrossRef P. Solk, K. Gavin, J. Fanning, W. Welch, G. Lloyd, A. Cottrell, A. Nielsen, C.A.Santa. Maria, W. Gradishar, S.A. Khan, S. Kulkarni, J. Siddique, S.M. Phillips, Feasibility and acceptability of intensive longitudinal data collection of activity and patient-reported outcomes during chemotherapy for breast cancer. Qual. Life Res 28, 3333 (2019).CrossRef
26.
go back to reference M.J. Sliwinski, J.A. Mogle, J. Hyun, E. Munoz, J.M. Smyth, R.B. Lipton, Reliability and validity of ambulatory cognitive assessments. Assessment 25, 14 (2018).CrossRef M.J. Sliwinski, J.A. Mogle, J. Hyun, E. Munoz, J.M. Smyth, R.B. Lipton, Reliability and validity of ambulatory cognitive assessments. Assessment 25, 14 (2018).CrossRef
27.
go back to reference S. Schneider, D.U. Junghaenel, F.J. Keefe, J.E. Schwartz, A.A. Stone, J.E. Broderick, Individual differences in the day-to-day variability of pain, fatigue, and well-being in patients with rheumatic disease: associations with psychological variables. Pain 153, 813 (2012).CrossRef S. Schneider, D.U. Junghaenel, F.J. Keefe, J.E. Schwartz, A.A. Stone, J.E. Broderick, Individual differences in the day-to-day variability of pain, fatigue, and well-being in patients with rheumatic disease: associations with psychological variables. Pain 153, 813 (2012).CrossRef
28.
go back to reference V.B. Boesen, T. Christoffersen, T. Watt, S.W. Borresen, M. Klose, U. Feldt-Rasmussen, PlenadrEMA: effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments: a study protocol for an open-label switch pilot study. BMJ Open. 8, 19487 (2018). V.B. Boesen, T. Christoffersen, T. Watt, S.W. Borresen, M. Klose, U. Feldt-Rasmussen, PlenadrEMA: effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments: a study protocol for an open-label switch pilot study. BMJ Open. 8, 19487 (2018).
29.
go back to reference E.M.A. Smets, B. Garssen, B. Bonke, J.C.J.M. De Haes, The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J. Psychosom. Res. 39, 315 (1995).CrossRef E.M.A. Smets, B. Garssen, B. Bonke, J.C.J.M. De Haes, The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J. Psychosom. Res. 39, 315 (1995).CrossRef
30.
go back to reference P. Cramon, Å.K. Rasmussen, S.J. Bonnema, J.B. Bjorner, U. Feldt-Rasmussen, M. Groenvold, L. Hegedüs, T. Watt, Development and implementation of PROgmatic: a clinical trial management system for pragmatic multi-centre trials, optimised for electronic data capture and patient-reported outcomes. Clin. Trials 11, 344 (2014).CrossRef P. Cramon, Å.K. Rasmussen, S.J. Bonnema, J.B. Bjorner, U. Feldt-Rasmussen, M. Groenvold, L. Hegedüs, T. Watt, Development and implementation of PROgmatic: a clinical trial management system for pragmatic multi-centre trials, optimised for electronic data capture and patient-reported outcomes. Clin. Trials 11, 344 (2014).CrossRef
31.
go back to reference J.D. Fisk, P.G. Ritvo, L. Ross, D.A. Haase, T.J. Marrie, W.F. Schlech, Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin. Infect. Dis. 18, 79 (1994).CrossRef J.D. Fisk, P.G. Ritvo, L. Ross, D.A. Haase, T.J. Marrie, W.F. Schlech, Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin. Infect. Dis. 18, 79 (1994).CrossRef
32.
go back to reference J.E. Ware, C.D. Sherbourne, The MOS 36-ltem short-form health survey (SF-36): I. Conceptual framework and item selection. Med. Care 30, 473 (1992).CrossRef J.E. Ware, C.D. Sherbourne, The MOS 36-ltem short-form health survey (SF-36): I. Conceptual framework and item selection. Med. Care 30, 473 (1992).CrossRef
33.
go back to reference A. Purcell, J. Fleming, S. Bennett, B. Burmeister, T. Haines, Determining the minimal clinically important difference criteria for the multidimensional fatigue inventory in a radiotherapy population. Support. Care Cancer 18, 307 (2010).CrossRef A. Purcell, J. Fleming, S. Bennett, B. Burmeister, T. Haines, Determining the minimal clinically important difference criteria for the multidimensional fatigue inventory in a radiotherapy population. Support. Care Cancer 18, 307 (2010).CrossRef
34.
go back to reference J. Cohen, Statistical power analysis for the behavioral sciences (Taylor & Francis Inc, New York, 2013). J. Cohen, Statistical power analysis for the behavioral sciences (Taylor & Francis Inc, New York, 2013).
35.
go back to reference A.A. Stone, J.E. Schwartz, D. Schkade, N. Schwarz, A. Krueger, D. Kahneman, A population approach to the study of emotion: diurnal rhythms of a working day examined with the day reconstruction method. Emotion 6, 139 (2006).CrossRef A.A. Stone, J.E. Schwartz, D. Schkade, N. Schwarz, A. Krueger, D. Kahneman, A population approach to the study of emotion: diurnal rhythms of a working day examined with the day reconstruction method. Emotion 6, 139 (2006).CrossRef
Metadata
Title
The effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments
Authors
Victor Brun Boesen
Stina Willemoes Borresen
Thea Christoffersen
Marianne Klose
Torquil Watt
Ulla Feldt-Rasmussen
Publication date
01-02-2021
Publisher
Springer US
Published in
Endocrine / Issue 2/2021
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02507-x

Other articles of this Issue 2/2021

Endocrine 2/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.